Castrate-resistant Prostate Cancer Market, by Therapy Type (Hormonal Therapy, Immunotherapy, and Chemotherapy), by Drug Class (Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Microtubule Inhibitor, and Others), by Route of Administration (Ora

Castrate-resistant Prostate Cancer Market, by Therapy Type (Hormonal Therapy, Immunotherapy, and Chemotherapy), by Drug Class (Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Microtubule Inhibitor, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer that is resistant to testosterone-lowering treatments. Symptoms of mCRPC include: difficulty urinating, pain while passing urine, or blood in the urine, weight loss and shortness of breath. Hormonal therapies are used to treat CRPC such as abiraterone (Zytiga) with corticosteroids inhibit the chemical production of testosterone throughout the body. Zytiga is used in conjunction with prednisone, a powerful anti-inflammatory medication. Other treatments for CRPC include chemo and immunotherapies.

Market Dynamics

Market players are focused on raising awareness campaigns related to prostate cancer, which is expected to fuel growth of the global castrate-resistant prostate cancer market over the forecast period. For instance, on June 17, 2021, patient organization ZERO and Bayer AG, a global life sciences company, collaborated to launch 'We're Not Gonna Take It', a national prostate cancer education program. The campaign encourages men to get screened for prostate cancer and to learn more about risk factors such as family history and elevated prostate-specific antigen (PSA) levels.
Moreover, market players are focusing on product launches and approvals to strengthen their position in the global castrate-resistant prostate cancer market. For instance, on July 30 2019, Bayer AG, a global enterprise, announced that the U.S. Food and Drug Administration (FDA) approved Nubeqa (darolutamide), for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).

Furthermore, market players are focusing on research and development activities for the treatment of castrate-resistant prostate cancer, which is expected to drive growth of the global castrate-resistant prostate cancer market. For instance, on April 10 2021, Cardiff Oncology Inc., a clinical-stage biotechnology company in collaboration with scientists at the Massachusetts Institute of Technology's Center for Precision Cancer Medicine (MIT), announced that new gene signature and mechanistic analyses from its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer (mCRPC) were featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, April, 2021.

Key features of the study:
This report provides an in-depth analysis of global castrate-resistant prostate cancer market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global castrate-resistant prostate cancer market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and AstraZeneca plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global castrate-resistant prostate cancer market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global castrate-resistant prostate cancer market.
Detailed Segmentation:
Global Castrate-resistant Prostate Cancer Market, By Therapy Type:
Hormonal Therapy
Immunotherapy
Chemotherapy
Global Castrate-resistant Prostate Cancer Market, By Drug Class:
Antineoplastic
Non-steroidal Antiandrogen
Corticosteroids
Microtubule Inhibitor
Others

Global Castrate-resistant Prostate Cancer Market, By Route of Administration:
Oral
Injectable

Global Castrate-resistant Prostate Cancer Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Castrate-resistant Prostate Cancer Market, By Region:
North America
By Therapy Type:
Hormonal Therapy
Immunotherapy
Chemotherapy
By Drug Class:
Antineoplastic
Non-steroidal Antiandrogen
Corticosteroids
Microtubule Inhibitor
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Therapy Type:
Hormonal Therapy
Immunotherapy
Chemotherapy
By Drug Class:
Antineoplastic
Non-steroidal Antiandrogen
Corticosteroids
Microtubule Inhibitor
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Therapy Type:
Hormonal Therapy
Immunotherapy
Chemotherapy
By Drug Class:
Antineoplastic
Non-steroidal Antiandrogen
Corticosteroids
Microtubule Inhibitor
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Therapy Type:
Hormonal Therapy
Immunotherapy
Chemotherapy
By Drug Class:
Antineoplastic
Non-steroidal Antiandrogen
Corticosteroids
Microtubule Inhibitor
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East
By Therapy Type:
Hormonal Therapy
Immunotherapy
Chemotherapy
By Drug Class:
Antineoplastic
Non-steroidal Antiandrogen
Corticosteroids
Microtubule Inhibitor
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Therapy Type:
Hormonal Therapy
Immunotherapy
Chemotherapy
By Drug Class:
Antineoplastic
Non-steroidal Antiandrogen
Corticosteroids
Microtubule Inhibitor
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Sanofi*
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
Johnson & Johnson Services Inc.
Pfizer Inc.
Astellas Pharma Inc.
Bayer AG
Bristol Myers Squibb
Merck Sharp & Dohme
Novartis International AG
Eli Lilly & Company
AstraZeneca plc.

“*” marked represents similar segmentation in other categories in the respective section.